Per J Greisen

Title: The Innovations of Per J Greisen

Introduction

Per J Greisen is a notable inventor based in Belmont, MA (US), recognized for his contributions to the field of biotechnology. He holds a total of four patents, showcasing his innovative approach to solving complex medical challenges. His work primarily focuses on advancements in coagulation therapies, particularly for conditions such as hemophilia A.

Latest Patents

Among his latest patents is the development of highly potent ISVD compounds capable of substituting for FVIII(A). This invention provides ISVD polypeptide derivatives that can bind to coagulation Factor IX(a) and Factor X(a). These derivatives are designed to have a long half-life, allowing for effective subcutaneous and peroral administration. This innovation is particularly significant for the treatment of hemophilia A, including cases with inhibitors and acquired hemophilia A. Another notable patent involves improved procoagulant antibodies, including bispecific antibodies that bind to coagulation Factor IX (FIX) or its activated form, Factor IXa (FIXa). These antibodies promote FX activation by FIXa and offer methods and compositions for treating coagulopathies such as hemophilia A.

Career Highlights

Per J Greisen has made significant strides in his career, particularly through his work at Novo Nordisk A/S. His innovative contributions have positioned him as a key figure in the development of new therapeutic options for patients with bleeding disorders. His expertise in the field has led to advancements that improve patient outcomes and enhance treatment efficacy.

Collaborations

Throughout his career, Greisen has collaborated with esteemed colleagues, including Karina Thorn and Bjarne Gram Hansen. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the advancement of research in coagulation therapies.

Conclusion

Per J Greisen's work exemplifies the spirit of innovation in the biotechnology sector. His patents and contributions to coagulation therapies have the potential to significantly impact the treatment of hemophilia A and related conditions. His dedication to advancing medical science continues to inspire future innovations in the field.